WAVE Life Sciences (NASDAQ:WVE) Hits New 12-Month Low – Here’s What Happened

WAVE Life Sciences Ltd. (NASDAQ:WVE) hit a new 52-week low during trading on Thursday . The stock traded as low as $4.63 and last traded at $4.6940, with a volume of 324311 shares. The stock had previously closed at $4.81.

Analysts Set New Price Targets

A number of research firms have recently commented on WVE. UBS Group set a $13.00 target price on shares of WAVE Life Sciences in a report on Monday, August 3rd. Wall Street Zen cut shares of WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 1st. HC Wainwright reiterated a “buy” rating on shares of WAVE Life Sciences in a research report on Monday, August 3rd. New Street Research set a $13.00 target price on shares of WAVE Life Sciences in a research report on Thursday, June 11th. Finally, Mizuho cut their target price on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, WAVE Life Sciences presently has an average rating of “Moderate Buy” and an average price target of $22.31.

WAVE Life Sciences Price Performance

The company has a fifty day moving average price of $5.58 and a two-hundred day moving average price of $7.35. The company has a market capitalization of $927.12 million, a P/E ratio of -4.32 and a beta of -1.30.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). WAVE Life Sciences had a negative net margin of 309.73% and a negative return on equity of 50.36%. The business had revenue of $2.27 million during the quarter, compared to the consensus estimate of $7.45 million. As a group, sell-side analysts forecast that WAVE Life Sciences Ltd. will post -1.11 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $5.29, for a total value of $67,183.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Heidi Wagner sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total value of $42,070.00. Following the transaction, the director directly owned 44,930 shares of the company’s stock, valued at approximately $270,029.30. This represents a 13.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 23,564 shares of company stock valued at $132,476 over the last 90 days. 24.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On WAVE Life Sciences

A number of hedge funds have recently made changes to their positions in WVE. GSK plc bought a new stake in shares of WAVE Life Sciences in the 4th quarter valued at $310,177,000. Darwin Global Management Ltd. bought a new position in WAVE Life Sciences during the fourth quarter worth $125,168,000. Readystate Asset Management LP bought a new position in WAVE Life Sciences during the second quarter worth $27,465,000. Price T Rowe Associates Inc. MD lifted its holdings in WAVE Life Sciences by 83.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company’s stock valued at $125,927,000 after buying an additional 3,362,880 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in WAVE Life Sciences by 20.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after buying an additional 2,500,000 shares during the period. 89.73% of the stock is currently owned by institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.